psilocybin (COMP360) / Compass Pathways 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...234567891011121314»
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Review, Journal:  Psychedelic-Assisted Group Therapy: A Systematic Review. (Pubmed Central) -  May 25, 2020   
    Contemporary research with classic psychedelic drugs (e.g., lysergic acid diethylamide (LSD) and psilocybin) is indebted to the twentieth-century researchers and clinicians who generated valuable clinical knowledge of these substances through experimentation...Publications are characterized by their clinical approach, experimental method, and clinical outcomes. Given the renewed interest in the clinical use of psychedelic medicines, this review aims to stimulate hypotheses to be tested in future research on psychedelic-assisted psychotherapy, group process, and interpersonal functioning.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  The Past and Future of Psychedelic Science: An Introduction to This Issue. (Pubmed Central) -  May 25, 2020   
    Studies are taking place in research institutions and in private practice sites supported by non-profit and for-profit organizations, as well as individual investigators. This research includes clinical trials with MDMA-assisted therapy for the treatment of PTSD, alcoholism, and social anxiety, and psilocybin clinical studies for depression and addiction, as well as the ability of psychedelics to catalyze spiritual or mystical experiences and inspire creativity, and into the neuroscientific understanding the effects of psychedelic substances on our nervous system.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Review, Journal:  Psychedelic treatment of functional neurological disorder: a systematic review. (Pubmed Central) -  May 22, 2020   
    There has been recent interest in the therapeutic potential of psychedelics such as psilocybin and lysergic acid diethylamide (LSD), and in recent studies psychedelics have shown promise in treating a range of neuropsychiatric conditions...All included studies were of low quality, often lacking control groups and valid outcome measures. Although no conclusions on efficacy may be drawn from these data, further research may help to determine whether psychedelics offer a feasible, safe and effective treatment for FND.
  • ||||||||||  ibogaine / DemeRx, ketamine / Generic mfg., psilocybin (COMP360) / Compass Pathways
    Journal:  Neurotrophic mechanisms of psychedelic therapy (Pubmed Central) -  May 19, 2020   
    Serotonergic psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are gaining attention as potential treatments for depression and addiction, similarly to 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD), and ibogaine for addiction...Finally, we show how ibogaine could exert its anti-addictive properties through a completely different neurotrophic factor than other psychedelic drugs, the glial cell line-derived neurotrophic factor (GDNF). While the current literature concerning the psychiatric applications of psychedelic therapy is encouraging, it remains to be determined whether their benefits could be obtained without their psychotomimetic effects, or concerns over potential toxicity.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Self-reported negative outcomes of psilocybin users: A quantitative textual analysis. (Pubmed Central) -  May 19, 2020   
    The use of multiple doses of psilocybin in the same session or its combination with other substances was linked to the occurrence of long-term negative outcomes, while the use of mushrooms in single high doses was linked to medical emergencies. These results can be useful for a better understanding of the effects of psilocybin use, guiding harm-reduction initiatives.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Preclinical, Journal:  In vivo production of psilocybin in E. coli. (Pubmed Central) -  Apr 23, 2020   
    Further enhancements to this genetically superior strain were achieved through fermentation optimization, ultimately resulting in a fed-batch fermentation study, with a production titer of 1.16 g/L of psilocybin. This is the highest psilocybin titer achieved to date from a recombinant organism and a significant step towards demonstrating the feasibility of industrial production of biologically-derived psilocybin.